Upcoming event

Tags

[68Ga]Ga-DPI-4452 PET/CT, 3D reconstruction, adjuvant pembrolizumab, advanced RCC, Article of the Month, Artificial intelligence, ASCO GU22, ASCO21, AUA21, augmented reality, belzutifan, biomarkers, Cabozantinib, CAIN trial, Carcinoma, CARE1 trial, ccRCC, CheckMate-214, CheckMate-9ER, Checkpoint Inhibitor, Chronic kidney disease, clampless surgery, clear cell renal cell carcinoma, Cryosurgery, cystic masses, diagnostics, durvalumab, EAU, EAU21, EAU22, EMUC2026, EMUC21, EMUC22, enucleoresection, ERUS 2026, ERUS22, ESMO21, ESMO25, expert interview, first-line, first-line treatment, Frail patient​, Glomerular filtration rate, Guidelines, histology, histotripsy, imaging, IMDC risk model, immunotherapy, International Metastatic Renal Cell Carcinoma Database Consortium, intraoperative cyst rupture, intraoperative ultrasound, Kidney cancer, kidney-preserving, Laparoscopy, lenvatinib, localised renal cell carcinoma, Lymph node metastases, Lymph nodes, Metastasectomy, metastatic clear-cell renal cell carcinoma, metastatic disease, metastatic RCC, MK-1308A, Mortality, mRCC, neoadjuvant immunotherapy, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, oligometastatic renal cell carcinoma, omRCC, Overall survival, papillary tumour, Partial nephrectomy, patient reported outcomes, PD-L1+, PE-PE trial, pembrolizumab, precision therapy, Prognostication, quality of life, Radical nephrectomy, Radical surgery, RAMPART trial, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, resected renal cell carcinoma, risk stratification, robot-assisted partial nephrectomy, Robotic, robotic partial nephrectomy, Robotic prostatectomy, Robotic surgery, selective clamping, stereotactic body radiation therapy, Survival outcome, Suture, sutureless partial nephrectomy, Targeted therapies, TKIs, Treatment response, tumour enucleation, tumour genomics, tumour pseudocapsule rupture, tyrosine kinase inhibitors, Urological surgery, UROonco2025, UROonco24, UROonco25, UROwebinar, Webinar, zero-ischaemia surgery
Show all

Should partial nephrectomy be considered “elective” in patients with stage 2 chronic kidney disease? A comparative analysis of functional and survival outcomes after radical and partial nephrectomy

World Journal of Urology, February 2019

Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma

January, 2019

The role of non-tumour renal biopsy in patients treated with radical nephrectomy

March 2019

Individualized immune-related gene signature predicts immune status and oncologic outcomes in clear cell renal call carcinoma patients

March 2019

Identification of a microRNA profile in urine with diagnostic and prognostic value for clear cell renal cell carcinoma

March 2019

Clinical utility of the mutational landscape and fragment size of circulating tumor DNA in renal cell carcinoma

March 2019

Below safety limits, every unit of glomerular filtration rate counts: assessing the relationship between renal function and cancer-specific mortality in renal cell carcinoma

European Urology, Volume 74, Issue 5, November 2018, Pages 661-667

Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

J Urol., January 2017, Pages 44-49

Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR)

European Urology 2018 Oct 11

Suture techniques during laparoscopic and robot-assisted partial nephrectomy: a systematic review and quantitative synthesis of peri-operative outcomes

BJU Int. 2018 Sep 14

Bosniak Classification for Complex Renal Cysts Reevaluated: A Systematic Review

J Urol. , Volume 198, Issue 1, July 2017, Pages 12-21

Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors

J Clin Oncol

PreviousNext